Navigation Links
Robbins & Myers Schedules Second Quarter Fiscal 2008 Financial Results Conference Call
Date:3/11/2008

DAYTON, Ohio, March 11 /PRNewswire-FirstCall/ -- Robbins & Myers, Inc. (NYSE: RBN) announced today that it will be releasing its second quarter fiscal 2008 financial results for the period ended February 29, 2008, after market close on Wednesday, March 26, 2008. A live webcast of the conference call will be held at 2:00 p.m., EDT on Thursday, March 27, 2008 with Peter C. Wallace, President and Chief Executive Officer, and Christopher M. Hix, Vice President and Chief Financial Officer. They will discuss the Company's performance and respond to questions from the financial community.

Robbins & Myers invites interested investors to listen to the webcast, which will be broadcast live on its website http://www.robn.com. A webcast replay will be available at the website and a telephonic replay will be available beginning 4:00 p.m., EDT March 27, 2008, by dialing +1-888-286-8010 in the U.S. and entering conference ID # 30887500. For those outside the U.S., the international replay number is +1-617-801-6888 with the same ID number.

Robbins & Myers, Inc. is a leading supplier of highly-engineered, application-critical equipment and systems to energy, chemical, pharmaceutical and industrial markets.


'/>"/>
SOURCE Robbins & Myers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Robbins & Myers to Present at Gabelli Conference
2. Robbins & Myers to Present at Merrill Lynch Growth Industrials Conference December 13, 2007
3. Robbins & Myers Presenting at Bear Stearns 3rd Annual Commodities and Capital Goods Conference November 28, 2007
4. Robbins Bros. Gives Water at AIDS Walk L.A.
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
7. Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
8. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
9. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
10. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
11. American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
(Date:2/22/2017)... ... 22, 2017 , ... Gevir, a New Zealand-based company that focuses on developing ... coming soon to Amazon.com, the world’s largest online retailer. , The company ... an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Tillotts Pharma is ... Berlin office was opened in January ... The portfolio includes Entocort ® for the treatment ... of ulcerative colitis, and VistaPrep ® for bowel ... specialty pharmaceutical company focused on the treatment of gastrointestinal ...
(Date:2/23/2017)... MabVax Therapeutics Holdings, Inc . ... announces that it has received notice from the ... initiation a Phase I clinical trial with MVT-1075 ... ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel fully ... the phase I clinical trial in patients with ...
(Date:2/23/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ( ... and dermatology biopharmaceutical company, today announced that it has ... as special advisers to the Company,s Board of ... board on financial and corporate strategy. Provectus ... of up to $2.5 million from Eric Wachter ...
Breaking Medicine Technology: